Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on October 29, 2018. The registrant is an emerging growth company incorporated in California. The filing serves to disclose a press release issued on the same date under Regulation FD (Item 7.01).
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural disclosure referencing an external press release (Exhibit 99.1) rather than a financial statement.
Material Changes
No material financial changes or comparative period data are detailed within the text of this Form 8-K. The report solely indicates the issuance of a press release.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words like "may," "will," or "expects" are forward-looking and subject to risks.
- Risk Factors: Specific risks are not listed in this text but are referenced as being contained in the company's most recent Form 10-K and Form 10-Q filings.
- Management Commentary: No specific commentary is provided in the body of this report; the content is limited to the incorporation of the press release by reference.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Press Release dated October 29, 2018) to understand the specific event triggering this filing.
- Confirm the company name is OncoCyte Corporation, as the input metadata referenced "Insight Molecular Diagnostics Inc."
- Review the most recent Form 10-K and 10-Q for detailed risk factors and financial data not present in this 8-K.
- Note that the registrant has elected to use the extended transition period for complying with new financial accounting standards as an emerging growth company.